Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2016

01-03-2016 | Case report

Tolterodine

Pseudoporphyria: case report

Published in: Reactions Weekly | Issue 1/2016

Login to get access

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
…
Literature
Gyldenlove M, et al. Pseudoporphyria - a case report. Journal of the European Academy of Dermatology and Venereology 29: 827, No. 4, Apr 2015 - Denmark
Metadata
Title
Tolterodine
Pseudoporphyria: case report
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2016
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-016-15632-8

Other articles of this Issue 1/2016

Reactions Weekly 1/2016 Go to the issue

Case report

Moxifloxacin

Case report

Rabies vaccine

Clinical study

Flibanserin for HSDD: little benefit, increased nausea and dizziness

Case report

Adalimumab/etanercept/infliximab

News item

Limited evidence of ischaemic colitis with pseudoephedrine

Case report

Carboplatin/etoposide